With GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) facing fresh allegations of bribery, this time in Poland, Owain Bennallack focuses on those made in relation to Iraq and asks whether this newsflow ought to diminish the appeal of the company as a share…
(Video) GlaxoSmithKline plc’s Bribery Allegations
GlaxoSmithKline plc (LON:GSK) faces fresh allegations of bribery abroad.
The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.